greeksoup/ stock research

Roivant Sciences (ROIV) Q2 FY2025 earnings: revenue $2 million, down 64.9% on the year

Roivant Sciences Ltd. (ROIV) reported revenue of $2 million for Q2 FY2025, the quarter ended 30 September 2025, down 64.9% on the same quarter a year earlier. Net income was -$114 million, and diluted earnings per share $-0.17. The figures are the company's own, from the 10-Q it filed with the SEC on 10 November 2025.

Revenue$2 milliondown 64.9%
Net income-$114 million
Diluted EPS$-0.17
QuarterQ2 FY2025ended 30 September 2025

The quarter, against the one before and a year earlier

LineQ2 FY2025Q1 FY2025Q2 FY2024Change on the year
Revenue1.62.24.5-64.9%
Research and development165153143+15.0%
Operating income-306-285-342n/a
Operating margin-19492.9%-13130.0%-7636.0%
Pre-tax income-159-269-224n/a
Income tax7.04.612.5-43.9%
Net income-114-223-230n/a
Net margin-7225.9%-10292.9%-5143.8%
Diluted EPS-$0.17-$0.33-$0.31n/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ2 FY2025Q1 FY2025Q2 FY2024Change on the year
Operating cash flow-186-204-267n/a
Capital expenditure7.84.01.0+688.0%
Free cash flow-194-208-268n/a
Free cash flow margin-12317.8%-9604.5%-5984.4%
Cash from investing120-1,086-3,294n/a
Cash from financing62.6-188-109n/a
Depreciation and amortisation0.91.14.8-81.0%
Share-based compensation81.882.271.7+14.2%
Buybacks0.0208106n/a
Diluted shares, weighted681m680m735m-7.4%
Shares outstanding at period end690m682m733m-5.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ2 FY2025Q1 FY2025Q2 FY2024Change on the year
Shareholders' equity4,3624,3465,153-15.3%
Non-controlling interest443470427+3.8%
Debt0.00.0n/an/a
Operating lease liabilities89.890.343.2+108.0%
Other liabilities167126583-71.3%
Total liabilities and equity5,0635,0336,206-18.4%
Fixed assets25.714.913.7+87.7%
Investments3,1493,2653,428-8.1%
Cash and equivalents1,2371,2381,959-36.8%
Receivablesn/an/a1.9n/a
Other assets651515804-19.0%
Total assets5,0635,0336,206-18.4%

Quarterly results, the last 12 quarters

Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024 †Q2 FY2024Q3 FY2024Q4 FY2024 * †Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026
Revenue3.615.628.98.04.59.07.62.21.62.02.51.4
R&D115108121121143142145153165165199202
SG&A164197170149n/an/an/an/an/an/an/an/a
Operating income-2145,127-266-102-342-274-285-285-306-339415-366
Operating margin-5863%32949%-919%-1280%-7636%-3043%-3764%-13130%-19493%-16966%16478%-25381%
Interest expense9.29.47.213.4n/an/an/an/an/an/an/an/a
Pre-tax income-2415,154-191-19.6-224-235-203-269-159-290454-295
Tax raten/a0%n/an/an/an/an/an/an/an/a22%n/a
Net income-3045,096-15195.3-230169-206-223-114-266303-190
Net margin-8342%32748%-522%1193%-5144%1878%-2728%-10293%-7226%-13301%12024%-13165%
Diluted EPS-$0.40$6.03-$0.19$0.12-$0.31$0.23-$0.28-$0.33-$0.17-$0.38$0.34-$0.26
Operating cash flow-196-210-108-193-267-207-173-204-186-196-164-271
Capital expenditure0.30.40.31.01.01.80.84.07.8n/a1.30.4
Free cash flow-197-211-109-194-268-209-173-208-194n/a-165-271
Buybacks0.00.00.06481062432952080.00.0n/a207
Shares outstanding801m805m807m739m733m720m696m682m690m710m720m723m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2025, filed 10 November 2025, accession 0001635088-25-000016: the filing on EDGAR. All of Roivant Sciences Ltd.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install